Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 151.6% in December

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, an increase of 151.6% from the November 30th total of 1,590,000 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average daily volume of 93,440,000 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

TNXP traded down $0.03 on Friday, hitting $0.34. 61,910,764 shares of the company traded hands, compared to its average volume of 30,361,879. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $14.08. The company has a 50 day moving average of $0.22 and a 200-day moving average of $0.41. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $63.84 million, a PE ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Sell-side analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.